The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II trial of bevacizumab and rucaparib in recurrent carcinoma of the cervix or endometrium.
 
Camille Catherine Jackson
Consulting or Advisory Role - Clovis Oncology (Inst); GlaxoSmithKline/Tesaro (Inst)
Research Funding - Clovis Oncology (Inst); Genentech (Inst); Lilly (Inst)
 
Leigh Cantrell
No Relationships to Disclose
 
Britt Kristina Erickson
Research Funding - Clovis Oncology (Inst)
 
Kathleen N. Moore
Honoraria - Physicans' Education Resource; Prime Oncology; Research To Practice
Consulting or Advisory Role - Abbvie; Aravive; AstraZeneca (Inst); Eisai; Genentech/Roche; Immunogen; Merck; Mersana (Inst); Myriad Genetics; Pfizer/EMD Serono; TESARO (Inst); Vavotar Life Sciences; VBL Therapeutics
Research Funding - Abbvie/Stemcentrx (Inst); Advaxis (Inst); Agenus (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Forty Seven (Inst); Genentech (Inst); Immunogen (Inst); Lilly (Inst); Lilly Foundation (Inst); Merck (Inst); Novartis Pharmaceuticals UK Ltd. (Inst); Novogen (Inst); PTC Therapeutics (Inst); Regeneron (Inst); Stem CentRx (Inst); Takeda (Inst); Tesaro (Inst); Verastem (Inst)
 
Linda R. Duska
Consulting or Advisory Role - CUE Biopharma; Genentech/Roche; Inovio Pharmaceuticals; Merck; Morphotek; Tesaro
Research Funding - Abbvie (Inst); Aduro Biotech (Inst); Advaxis (Inst); Aeterna Zentaris (Inst); Bristol-Myers Squibb (Inst); Cerulean Pharma (Inst); Cerulean Pharma (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Leap Therapeutics (Inst); Ludwig Institute for Cancer Research (Inst); Merck (Inst); Millennium (Inst); Morab (Inst); Morphotek (Inst); Novartis (Inst); Pfizer (Inst); Syndax (Inst); Syndax (Inst); Tesaro (Inst)
 
Debra L. Richardson
Consulting or Advisory Role - AstraZeneca; Bayer; Deciphera; Foundation Medicine; Genentech/Roche; GlaxoSmithKline; Ipsen; Mersana; Tesaro
Research Funding - Aravive (Inst); ArQule (Inst); AstraZeneca (Inst); Deciphera (Inst); Five Prime Therapeutics (Inst); Fujifilm (Inst); Genentech (Inst); Harpoon therapeutics (Inst); Hookipa Biotech (Inst); Innovent Biologics (Inst); Karyopharm Therapeutics (Inst); Lycera (Inst); Merck (Inst); Mersana (Inst); Roche (Inst); Syros Pharmaceuticals (Inst); Tesaro (Inst)
 
Lisa Michelle Landrum
No Relationships to Disclose
 
Laura L. Holman
No Relationships to Disclose
 
Joan L. Walker
Research Funding - Gynecologic Oncology Group/NRG (Inst)
 
Robert S. Mannel
Consulting or Advisory Role - Tesaro (Inst)
 
Katherine M. Moxley
Consulting or Advisory Role - Clovis Oncology (Inst); Tessa Therapeutics (Inst)
 
Lurdes Queimado
No Relationships to Disclose
 
Kai Ding
No Relationships to Disclose
 
Andrew Cohoon
No Relationships to Disclose
 
Sara Vesely
No Relationships to Disclose
 
Lauren E. Dockery
No Relationships to Disclose